Esophageal Cancer - Pipeline Review, H2 2014


#235139

244pages

Global Markets Direct

$ 2000

In Stock

Esophageal Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Esophageal Cancer - Pipeline Review, H2 2014, provides an overview of the Esophageal Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Esophageal Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Esophageal Cancer - Overview 9
Pipeline Products for Esophageal Cancer - Comparative Analysis 10
Esophageal Cancer - Therapeutics under Development by Companies 11
Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes 14
Esophageal Cancer - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Esophageal Cancer - Products under Development by Companies 18
Esophageal Cancer - Products under Investigation by Universities/Institutes 21
Esophageal Cancer - Companies Involved in Therapeutics Development 22
Advantagene, Inc. 22
Advaxis, Inc. 23
Amgen Inc. 24
ArQule, Inc. 25
Aslan Pharmaceuticals Pte. Ltd. 26
AstraZeneca PLC 27
AVEO Pharmaceuticals, Inc. 28
Boehringer Ingelheim GmbH 29
Bristol-Myers Squibb Company 30
Celgene Corporation 31
Cerulean Pharma, Inc. 32
Daiichi Sankyo Company, Limited 33
Genmab A/S 34
GlaxoSmithKline plc 35
Glycotope GmbH 36
Hutchison MediPharma Limited 37
ImmunoFrontier, Inc. 38
ImmunoGen, Inc. 39
Immunomedics, Inc. 40
Karyopharm Therapeutics, Inc. 41
Mebiopharm Co., Ltd. 42
Meiji Seika Pharma Co., Ltd. 43
Merrimack Pharmaceuticals, Inc. 44
Novartis AG 45
Omeros Corporation 46
Omnitura Therapeutics Inc. 47
Oncolys BioPharma Inc. 48
Ono Pharmaceutical Co., Ltd. 49
Patrys Limited 50
Pfizer Inc. 51
Precision Biologics, Inc. 52
Recepta Biopharma S.A. 53
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 54
Supratek Pharma Inc. 55
Synta Pharmaceuticals Corp. 56
Takara Bio Inc. 57
Transgene Biotek Limited 58
Esophageal Cancer - Therapeutics Assessment 59
Assessment by Monotherapy Products 59
Assessment by Target 60
Assessment by Mechanism of Action 63
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 70
1-BB1 - Drug Profile 70
ADXS-HER2 - Drug Profile 72
afatinib - Drug Profile 73
alpelisib - Drug Profile 77
AMG-337 - Drug Profile 79
binimetinib - Drug Profile 80
BMS-833923 - Drug Profile 84
Cell Therapy 1 for Oncology - Drug Profile 86
Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile 87
cetuximab biobetter - Drug Profile 88
CRLX-101 - Drug Profile 89
dacomitinib - Drug Profile 91
DKN-01 - Drug Profile 93
doxorubicin - Drug Profile 95
ficlatuzumab - Drug Profile 97
ganetespib - Drug Profile 100
gefitinib - Drug Profile 104
Gene Therapy for Esophageal Cancer - Drug Profile 109
Gene Therapy to Activate p53 for Oncology - Drug Profile 110
GSK-2256098 - Drug Profile 111
HMPL-813 - Drug Profile 113
HuMax-TF-ADC - Drug Profile 114
IMF-001 - Drug Profile 115
IMGN-289 - Drug Profile 116
IMMU-132 - Drug Profile 117
KML-001 - Drug Profile 118
LJM-716 - Drug Profile 120
MBP-426 - Drug Profile 122
MM-111 - Drug Profile 124
MMD-37K - Drug Profile 126
MVX-ONCO-1 - Drug Profile 127
NEO-201 - Drug Profile 128
nimotuzumab - Drug Profile 130
nivolumab (recombinant) - Drug Profile 133
OBP-301 - Drug Profile 138
OMN-54 - Drug Profile 140
Oncolytic Virus for Oncology - Drug Profile 142
paclitaxel albumin bound - Drug Profile 143
panitumumab - Drug Profile 147
PAT-LM1 - Drug Profile 150
patritumab - Drug Profile 151
rAAV-VICN003 - Drug Profile 153
RebmAb-400 - Drug Profile 154
rhLT28-171 - Drug Profile 155
selinexor - Drug Profile 156
Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile 159
Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile 160
Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile 161
talaporfin sodium - Drug Profile 162
TBI-1201 - Drug Profile 165
TBL-0805E - Drug Profile 167
tivantinib - Drug Profile 168
Vaccine for Esophageal Cancer - Drug Profile 171
Vaccine for Oncology - Drug Profile 172
varlitinib - Drug Profile 173
Esophageal Cancer - Recent Pipeline Updates 175
Esophageal Cancer - Dormant Projects 230
Esophageal Cancer - Discontinued Products 231
Esophageal Cancer - Product Development Milestones 232
Featured News & Press Releases 232
Appendix 239
Methodology 239
Coverage 239
Secondary Research 239
Primary Research 239
Expert Panel Validation 239
Contact Us 240
Disclaimer 240

List of Tables
Number of Products under Development for Esophageal Cancer, H2 2014 13
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 16
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Late Stage Development, H2 2014 19
Comparative Analysis by Clinical Stage Development, H2 2014 20
Comparative Analysis by Early Stage Development, H2 2014 21
Products under Development by Companies, H2 2014 22
Products under Development by Companies, H2 2014 (Contd..1) 23
Products under Development by Companies, H2 2014 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2014 25
Esophageal Cancer - Pipeline by Advantagene, Inc., H2 2014 26
Esophageal Cancer - Pipeline by Advaxis, Inc., H2 2014 27
Esophageal Cancer - Pipeline by Amgen Inc., H2 2014 28
Esophageal Cancer - Pipeline by ArQule, Inc., H2 2014 29
Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2014 30
Esophageal Cancer - Pipeline by AstraZeneca PLC, H2 2014 31
Esophageal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2014 32
Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 33
Esophageal Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 34
Esophageal Cancer - Pipeline by Celgene Corporation, H2 2014 35
Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 36
Esophageal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 37
Esophageal Cancer - Pipeline by Genmab A/S, H2 2014 38
Esophageal Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 39
Esophageal Cancer - Pipeline by Glycotope GmbH, H2 2014 40
Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H2 2014 41
Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H2 2014 42
Esophageal Cancer - Pipeline by ImmunoGen, Inc., H2 2014 43
Esophageal Cancer - Pipeline by Immunomedics, Inc., H2 2014 44
Esophageal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 45
Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2014 46
Esophageal Cancer - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2014 47
Esophageal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 48
Esophageal Cancer - Pipeline by Novartis AG, H2 2014 49
Esophageal Cancer - Pipeline by Omeros Corporation, H2 2014 50
Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2014 51
Esophageal Cancer - Pipeline by Oncolys BioPharma Inc., H2 2014 52
Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 53
Esophageal Cancer - Pipeline by Patrys Limited, H2 2014 54
Esophageal Cancer - Pipeline by Pfizer Inc., H2 2014 55
Esophageal Cancer - Pipeline by Precision Biologics, Inc., H2 2014 56
Esophageal Cancer - Pipeline by Recepta Biopharma S.A., H2 2014 57
Esophageal Cancer - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2014 58
Esophageal Cancer - Pipeline by Supratek Pharma Inc., H2 2014 59
Esophageal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 60
Esophageal Cancer - Pipeline by Takara Bio Inc., H2 2014 61
Esophageal Cancer - Pipeline by Transgene Biotek Limited, H2 2014 62
Assessment by Monotherapy Products, H2 2014 63
Number of Products by Stage and Target, H2 2014 65
Number of Products by Stage and Mechanism of Action, H2 2014 68
Number of Products by Stage and Route of Administration, H2 2014 71
Number of Products by Stage and Molecule Type, H2 2014 73
Esophageal Cancer Therapeutics - Recent Pipeline Updates, H2 2014 179
Esophageal Cancer - Dormant Projects, H2 2014 234
Esophageal Cancer - Discontinued Products, H2 2014 235

List of Figures
Number of Products under Development for Esophageal Cancer, H2 2014 13
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 15
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Late Stage Development, H2 2014 19
Comparative Analysis by Clinical Stage Development, H2 2014 20
Comparative Analysis by Early Stage Products, H2 2014 21
Assessment by Monotherapy Products, H2 2014 63
Number of Products by Top 10 Targets, H2 2014 64
Number of Products by Stage and Top 10 Targets, H2 2014 64
Number of Products by Top 10 Mechanism of Actions, H2 2014 67
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 67
Number of Products by Top 10 Routes of Administration, H2 2014 70
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 71
Number of Products by Top 10 Molecule Types, H2 2014 72
Number of Products by Stage and Top 10 Molecule Types, H2 2014 73